BAKER BROS. ADVISORS LP Q3 2023 Filing
Filed November 14, 2023
Portfolio Value
$17.4B
Holdings
101
Report Date
Q3 2023
Filing Type
13F-HR
All Holdings (101 positions)
| Stock | Value |
|---|---|
SGENUSDSeagen Inc. | $9.5T |
ONCBeiGene, Ltd. | $2.1T |
INCYIncyte Corporation | $2.1T |
ACADACADIA Pharmaceuticals Inc. | $893.3B |
BMRNBioMarin Pharmaceutical Inc. | $337.1B |
MDGLMadrigal Pharmaceuticals, Inc. | $225.6B |
RYTMRhythm Pharmaceuticals, Inc. | $153.7B |
ROIVRoivant Sciences Ltd. | $138.7B |
IMCRImmunocore Holdings plc | $130.8B |
—Invitae Corporation | $130.4B |
AKROAkero Therapeutics, Inc. | $119.8B |
ABCLAbCellera Biologics Inc. | $95.5B |
BCRXBioCryst Pharmaceuticals, Inc. | $90.0B |
REPLReplimune Group, Inc. | $78.3B |
TRDAEntrada Therapeutics, Inc. | $76.9B |
RVMDRevolution Medicines, Inc. | $74.5B |
ARGXargenx SE | $74.3B |
SWTXSpringWorks Therapeutics, Inc. | $69.4B |
KYMRKymera Therapeutics, Inc. | $66.0B |
IMTXImmatics N.V. | $65.3B |
MRTXEURMirati Therapeutics, Inc. | $61.4B |
KNSAKiniksa Pharmaceuticals, Ltd. | $48.8B |
RAREUltragenyx Pharmaceutical Inc. | $48.7B |
DNLIDenali Therapeutics Inc. | $47.3B |
PRLDPrelude Therapeutics Inc. | $31.3B |
KODKodiak Sciences Inc. | $31.2B |
NRIXNurix Therapeutics, Inc. | $30.5B |
BMEABiomea Fusion, Inc. | $29.0B |
IDYAIDEAYA Biosciences, Inc. | $28.7B |
CERSCerus Corporation | $27.9B |
AVTEAerovate Therapeutics, Inc. | $26.6B |
1K0IGM Biosciences, Inc. | $26.4B |
XENEXenon Pharmaceuticals Inc. | $25.7B |
CABACabaletta Bio, Inc. | $24.3B |
GLUEMonte Rosa Therapeutics, Inc. | $23.5B |
—DBV Technologies S.A. | $19.9B |
KRYSKrystal Biotech, Inc. | $19.7B |
VERVVerve Therapeutics, Inc. | $18.8B |
BCYCBicycle Therapeutics plc | $17.0B |
IMVTImmunovant, Inc. | $16.3B |
COGTCogent Biosciences, Inc. | $12.6B |
DAWNDay One Biopharmaceuticals, Inc. | $12.3B |
PRMEPrime Medicine, Inc. | $9.8B |
TSVT*2seventy bio, Inc. | $9.8B |
RLAYRelay Therapeutics, Inc. | $9.8B |
PACBPacific Biosciences of California, Inc. | $9.4B |
IM8NInsmed Incorporated | $8.7B |
ADAPYAdaptimmune Therapeutics plc | $8.6B |
TNGXTango Therapeutics, Inc. | $8.4B |
HRTXHeron Therapeutics, Inc. | $8.4B |
ARVNArvinas, Inc. | $8.1B |
TSHATaysha Gene Therapies, Inc. | $7.9B |
SANASana Biotechnology, Inc. | $7.7B |
—bluebird bio, Inc. | $7.6B |
SPRYARS Pharmaceuticals, Inc. | $7.6B |
SGMTSagimet Biosciences Inc. | $7.2B |
TCRXTScan Therapeutics, Inc. | $7.1B |
GONGeron Corporation | $6.5B |
—Athira Pharma, Inc. | $6.4B |
ALECAlector, Inc. | $6.3B |
—Invitae Corporation | $6.2B |
MIRMMirum Pharmaceuticals, Inc. | $6.0B |
EWTXEdgewise Therapeutics, Inc. | $6.0B |
SMMTSummit Therapeutics Inc. | $5.9B |
STOKStoke Therapeutics, Inc. | $5.9B |
HOOKGBPHOOKIPA Pharma Inc. | $5.0B |
MORFMorphic Holding, Inc. | $4.9B |
CELCCelcuity Inc. | $4.9B |
—Neoleukin Therapeutics, Inc. | $4.8B |
WHWKAadi Bioscience, Inc. | $4.8B |
OPTEYOpthea Limited | $4.7B |
NTRANatera, Inc. | $4.4B |
DSGNDesign Therapeutics, Inc. | $3.5B |
PRAXPraxis Precision Medicines, Inc. | $3.2B |
CMPXCompass Therapeutics, Inc. | $3.1B |
TLISTalis Biomedical Corporation | $2.9B |
GRCLGracell Biotechnologies Inc. | $2.9B |
SERASera Prognostics, Inc. | $2.8B |
PCVXVaxcyte, Inc. | $2.5B |
XNCRXencor, Inc. | $2.5B |
KALAKALA BIO, Inc. | $2.4B |
698Achilles Therapeutics plc | $2.3B |
IPSCCentury Therapeutics, Inc. | $2.3B |
—Affimed N.V. | $2.1B |
ISREURPerspective Therapeutics, Inc. | $2.1B |
TILInstil Bio, Inc. | $2.0B |
PMVPPMV Pharmaceuticals, Inc. | $2.0B |
ANABAnaptysBio, Inc. | $1.9B |
—POINT Biopharma Global Inc. | $1.7B |
5E7iTeos Therapeutics, Inc. | $1.6B |
CYPHLeap Therapeutics, Inc. | $1.6B |
ALGSAligos Therapeutics, Inc. | $1.6B |
—Mersana Therapeutics, Inc. | $1.4B |
VORVor Biopharma Inc. | $1.3B |
NVTA1EURInvitae Corporation | $1.1B |
RNAAvidity Biosciences, Inc. | $1.1B |
BCELAtreca, Inc. | $922.0M |
—Genetron Holdings Limited | $369.0M |
TARAProtara Therapeutics, Inc. | $333.0M |
FHTXFoghorn Therapeutics Inc. | $225.0M |
Page 1 of 2Next